EU/US business group to tackle counterfeiting:
This article was originally published in Clinica
Executive Summary
The fight against counterfeiting, a key concern to the new EU member states when it comes to medical device trade, is one of the priority areas for the Trans-Atlantic Business Dialogue as it continues its efforts to promote EU/US economic ties. Other priority areas highlighted at its meeting on June 25 were: open trade and security, intellectual property rights and capital markets and international accounting standards.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.